Renhaim Inc. participated in AusBiotech which is the largest bio-industry conference in Australia.
Renhaim Therapeutics, a key player in the mRNA-based biotech industry, made a significant impact at AusBiotech 2023, the Australian premier biotechnology conference. The event provided a platform for Renhaim to showcase its groundbreaking mRNA-based anti-cancer vaccine and cutting-edge osteoarthritis treatment technology currently under research and development. The company leveraged this opportunity to forge valuable connections within the global biotech community.
Throughout the conference, Renhaim Inc. engaged in approximately 30 partnering meetings, fostering collaborations with multinational pharmaceutical companies, overseas biotech firms, and prominent research institutes in Australia. Notably, on November 2, 2023, during the Korean Biotech Leaping towards Innovative Technology session, Director Jason Hur presented a comprehensive pitching deck highlighting the CDP project — a mRNA-based osteoarthritis therapeutics currently under development.
Tae-Jin Kang CEO of Renhaim emphasized the strategic significance of our participation, stating that "Continuing from last year and this year, Renhaim attended the AusBiotech as a member of the Korea-Australia exchange delegation. It provided a valuable platform to demonstrate our mRNA technology and pipeline. Our discussions and partnering meetings with exceptional companies hold the promise of fruitful collaborations, contributing to the overall growth of our company.
For further insights into our participation in AusBiotech 2023, please refer to the detailed article below. Stay tuned for updates on the positive outcomes anticipated from these collaborations.
